VEGFA and endometrial cancer: Bevacizumab (Avastin®, Genentech) is a recombinant humanized antibody against vascular endothelial growth factor-A (VEGF-A), and it has been studied as a single agent in women with recurrent endometrial cancer in study protocol GOG-229E [4].